These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 32844566)
1. Activity of Riminophenazines against Mycobacterium tuberculosis: A Review of Studies that Might be Contenders for Use as Antituberculosis Agents. Bvumbi MV ChemMedChem; 2020 Dec; 15(23):2207-2219. PubMed ID: 32844566 [TBL] [Abstract][Full Text] [Related]
2. Systematic evaluation of structure-activity relationships of the riminophenazine class and discovery of a C2 pyridylamino series for the treatment of multidrug-resistant tuberculosis. Liu B; Liu K; Lu Y; Zhang D; Yang T; Li X; Ma C; Zheng M; Wang B; Zhang G; Wang F; Ma Z; Li C; Huang H; Yin D Molecules; 2012 Apr; 17(4):4545-59. PubMed ID: 22510605 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents. Zhang D; Liu Y; Zhang C; Zhang H; Wang B; Xu J; Fu L; Yin D; Cooper CB; Ma Z; Lu Y; Huang H Molecules; 2014 Apr; 19(4):4380-94. PubMed ID: 24722591 [TBL] [Abstract][Full Text] [Related]
4. Xu J; Wang B; Fu L; Zhu H; Guo S; Huang H; Yin D; Zhang Y; Lu Y Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782992 [TBL] [Abstract][Full Text] [Related]
5. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Gopal M; Padayatchi N; Metcalfe JZ; O'Donnell MR Int J Tuberc Lung Dis; 2013 Aug; 17(8):1001-7. PubMed ID: 23541151 [TBL] [Abstract][Full Text] [Related]
6. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727 [TBL] [Abstract][Full Text] [Related]
7. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates. Zhang Z; Li T; Qu G; Pang Y; Zhao Y Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737 [TBL] [Abstract][Full Text] [Related]
8. Discovery of new riminophenazine analogues as antimycobacterial agents against drug-resistant Mycobacterium tuberculosis. Zhao X; Mei Y; Guo Z; Si S; Ma X; Li Y; Li Y; Song D Bioorg Chem; 2022 Nov; 128():105929. PubMed ID: 35701239 [TBL] [Abstract][Full Text] [Related]
9. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. Zhang D; Lu Y; Liu K; Liu B; Wang J; Zhang G; Zhang H; Liu Y; Wang B; Zheng M; Fu L; Hou Y; Gong N; Lv Y; Li C; Cooper CB; Upton AM; Yin D; Ma Z; Huang H J Med Chem; 2012 Oct; 55(19):8409-17. PubMed ID: 22931472 [TBL] [Abstract][Full Text] [Related]
11. Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis. Diriba G; Alemu A; Yenew B; Tola HH; Gamtesa DF; Mollalign H; Eshetu K; Moga S; Abdella S; Tollera G; Kebede A; Dangisso MH Int J Infect Dis; 2023 Jul; 132():50-63. PubMed ID: 37072053 [TBL] [Abstract][Full Text] [Related]
12. [Prospects for development of new antituberculous drugs]. Tomioka H Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents. Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612 [TBL] [Abstract][Full Text] [Related]
14. Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779 [TBL] [Abstract][Full Text] [Related]
15. Clofazimine: A useful antibiotic for drug-resistant tuberculosis. Mirnejad R; Asadi A; Khoshnood S; Mirzaei H; Heidary M; Fattorini L; Ghodousi A; Darban-Sarokhalil D Biomed Pharmacother; 2018 Sep; 105():1353-1359. PubMed ID: 30021373 [TBL] [Abstract][Full Text] [Related]
16. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Reddy VM; Nadadhur G; Daneluzzi D; O'Sullivan JF; Gangadharam PR Antimicrob Agents Chemother; 1996 Mar; 40(3):633-36. PubMed ID: 8851584 [TBL] [Abstract][Full Text] [Related]
18. 4H-1,3-Benzothiazin-4-one a Promising Class Against MDR/XDR-TB. de Souza MVN; Nogueira TCM Curr Top Med Chem; 2019; 19(8):567-578. PubMed ID: 30834835 [TBL] [Abstract][Full Text] [Related]
19. Pyrido[1,2-a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB. Pieroni M; Tipparaju SK; Lun S; Song Y; Sturm AW; Bishai WR; Kozikowski AP ChemMedChem; 2011 Feb; 6(2):334-42. PubMed ID: 21259445 [TBL] [Abstract][Full Text] [Related]
20. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda. Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]